Response to "Dose Rationale for Favipiravir Use in Patients Infected With SARS‐CoV‐2"
Authors:
- 21 May 2020
- journal article
- letter
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 108 (2) , 190
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitroAntiviral Research, 2020
- Dose Rationale for Favipiravir Use in Patients Infected With SARS‐CoV‐2Clinical Pharmacology & Therapeutics, 2020
- Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV InfectionClinical Pharmacology & Therapeutics, 2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020